Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. [electronic resource]
Producer: 20060607Description: 2252-60 p. digitalISSN:- 1527-7755
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Aminoquinolines
- Aniline Compounds
- Antineoplastic Agents -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- ErbB Receptors -- antagonists & inhibitors
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasms -- drug therapy
- Organic Chemicals -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.